Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive January 1, 2006 Cinquegrana & Lloyd	Legal: Shifting Perspective on Off-Label Promotion A recent court case points to the government's shifting perspective on how it prosecutes companies for promoting off-label. Instead of criminal charges, hefty corporate integrity agreements might be in store.
Pharmaceutical Executive September 1, 2008 Herschman & Khorover	The New Code Effective January 1st, sales reps will have a new standard for dealing with doctors with a revised "Code on Interactions with Healthcare Professionals."
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
Pharmaceutical Executive October 1, 2010	Getting Ready for Sunshine Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Pharmaceutical Executive March 1, 2009 Jill Wechsler	Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
Pharmaceutical Executive January 1, 2011 Jill Wechsler	Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead.
BusinessWeek March 11, 2010 Margaret Cronin Fisk et al.	Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.
National Defense March 2010 Fennelly & Epstein	Defense Contractors Must Effectively Monitor Consultants As corporate ethics and compliance programs are reviewed and strengthened to meet increasing competition and government requirements, companies may not recognize the risks posed by consultants and other agents.
Pharmaceutical Executive July 1, 2005 Jill Wechsler	Washington Report: The e-Bandwagon The federal government is driving e-Rx adoption by establishing standards that Medicare drug plans will have to adopt by 2009, and HHS officials are pushing to make this happen much earlier.
Managed Care August 2006 Martin Sipkoff	Off-Label Use Often Presents Conundrum for Health Plans Insurers recognize the clinical importance of off-label prescribing, but criteria are needed to avoid over-utilization.
Pharmaceutical Executive May 1, 2006 Ron Feemster	Teamsters v. Pfizer A New Jersey Teamsters local says Pfizer tricked them into paying for off-label Lipitor prescriptions. Do you have any questions about that? We do.
Pharmaceutical Executive September 1, 2010	Tracking Meetings in Troubled Times Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. What kind of impact is all this having on meetings and physician attendance?
Pharmaceutical Executive April 1, 2012	Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more.
Pharmaceutical Executive September 1, 2005 Diane West	Be Our Guest From training employees to forgoing lobster tail, hotels are putting the PhRMA Code on their menus.
BusinessWeek October 18, 2004 John Carey	"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be?
Pharmaceutical Executive December 1, 2006 Joanna Breitstein	Confessions of a Serial Whistleblower Interview with Peter Rost, author of Whistleblower: Confessions from a Healthcare Hitman, about what it was like after her blew the whistle on Pfizer and Wyeth.
Pharmaceutical Executive March 1, 2006 Jeff Brady	Sales Management: Spending Under Scrutiny Five states have already mandated that drug companies track, control, and report their marketing and sales spend directed at healthcare professionals, and many more states have legislation pending with distinct requirements.
Managed Care August 2001	GAO: Consultants Point Docs Toward Federal Law Violations The General Accounting Office has found that some health care consultants have been advising physicians to do things that conflict with federal laws and that may be unethical...
Pharmaceutical Executive June 1, 2006 Cindy D'Aoust	Who's Coming to Meetings? Need to attract the "right" physicians to a promotional meeting? Have to do it on a budget while following new compliance rules? Check out this new survey to see how the rest of pharma lives with a shifting promotional landscape.
Pharmaceutical Executive April 1, 2011	Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
BusinessWeek December 11, 2006 Michael Arndt	Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West.
Pharmaceutical Executive February 1, 2013 Jill Wechsler	Breakthrough Year for New Drugs More new medicines gained market approval, but marketers face resistance from payers looking to cut healthcare spending.
Pharmaceutical Executive September 1, 2010 Marylyn Donahue	With a Little Help from their Peers Physician meetings drive prescribing behavior, but what are the marketing meetings doctors prefer, and who are they listening to?
InternetNews August 16, 2007 Roy Mark	IBM, PWC Settle Kickback Charges IBM and PriceWaterhouseCoopers agreed today to pay $5.9 million to settle allegations that the companies made illegal kickbacks to obtain government technology contracts.
BusinessWeek February 5, 2007	The Doctor Won't See You Now A host of forces is now converging to clamp down on hard-driving, gift-toting pharmaceutical pitchmasters who have been ambushing physicians for the last decade.
Pharmaceutical Executive May 1, 2005 Robert Ullmann	Back Page: Unhealthy Justice More than any other healthcare law, the Medicare/Medicaid exclusion statute has distorted our criminal justice system with government fraud investigations. This well-intentioned but misguided law should be repealed.
Chemistry World November 11, 2013 Sarah Houlton	Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion.
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
The Motley Fool February 23, 2009 Brian Orelli	The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor.
Pharmaceutical Executive September 1, 2010	Where Prescribing Oncologists Go for Their Information, and Why Marketers need to understand how informal influencers are beginning to replace traditional channels as the favored way for doctors to receive product information from drug manufacturers, and, in turn, how best to leverage peer influence in designing effective meetings and events.
Pharmaceutical Executive September 1, 2005 Wilkenfeld & Braun-Davis	50 5 2005 Five things pharmaceutical companies can do to prepare for compliance in all 50 states.
Financial Planning June 1, 2007 John J. Bowen	Living Dangerously In today's hazardous world, affluent clients are looking to financial advisors for help in protecting more than their financial assets.
AskMen.com Roberto Rocha	Do You Need An Image Consultant? Behind every great man is a rich advisor. From presidents and CEOs to rap stars and basketball icons, all men of grand stature have likely profitted from the advice of an image consultant.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
Chemistry World June 6, 2013 Phillip Broadwith	Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud.
Pharmaceutical Executive June 1, 2006 Nancy Dreyer	Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials.
CIO July 30, 2013 Jennifer Lonoff Schiff	What to Look for When Hiring an IT Consultant How do you find the right IT consultant for your business and specific technology needs? IT executives share their tips and advice. We also suggest five questions you should ask all prospective candidates.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
Pharmaceutical Executive March 1, 2011 William Looney	John Castellani: Industry's Level Bet on a Dizzying Future Can PhRMA's own business model sync with industry's Pharm Exec takes a closer look at PhRMA's new leadership.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
Pharmaceutical Executive September 1, 2011	(Some) Booths Beckon What some pharma companies are doing about the increasing restrictions of face-to-face interaction between industry and prescribing physicians.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
Pharmaceutical Executive March 1, 2006 Dorfman & Maynor	Marketing to Professionals: Under the Influence Pharmaceutical marketers should target the doctors who affect change in the medical community.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive January 1, 2007 Jeffrey Zornitsky	Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers.